Earnings summaries and quarterly performance for Evofem Biosciences.
Executive leadership at Evofem Biosciences.
Board of directors at Evofem Biosciences.
Research analysts who have asked questions during Evofem Biosciences earnings calls.
David Amsellem
Piper Sandler Companies
4 questions for EVFM
Also covers: ABBV, ALKS, AMGN +27 more
RS
Ram Selvaraju
H.C. Wainwright
4 questions for EVFM
Also covers: ABEO, ADXN, BCPC +8 more
JH
Jeff Hung
Morgan Stanley
2 questions for EVFM
Also covers: ACAD, ALEC, BHVN +10 more
SL
Stacy Lee
Stifel
2 questions for EVFM
Also covers: SY
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
2 questions for EVFM
Also covers: AFMD, ALDX, ARCT +13 more
Annabel Samimy
Stifel Financial Corp.
1 question for EVFM
Also covers: ALT, APLS, CARA +14 more
AS
Annabel Sammy
Stifel
1 question for EVFM
Recent press releases and 8-K filings for EVFM.
Evofem Biosciences Reports Q3 2025 Financial Results and Business Updates
EVFM
Earnings
Revenue Acceleration/Inflection
M&A
- Evofem Biosciences reported net sales of $5.0 million for the third quarter of 2025, representing a 10% increase compared to the prior year quarter, and achieved operating income of $1.0 million in Q3 2025, a significant improvement from a $2.4 million loss in the prior year quarter.
- Total operating expenses decreased by 42% to $4.0 million in Q3 2025 compared to the prior year period.
- The net loss attributable to common stockholders was $1.7 million, or $0.01 per basic and diluted share, for Q3 2025, down from a $2.4 million net loss, or $0.02 per basic and diluted share, in Q3 2024.
- The company is advancing strategies to reduce manufacturing costs by approximately 50% for both PHEXX® and SOLOSEC® and submitted SOLOSEC® for marketing approval in the United Arab Emirates.
- Evofem terminated its merger agreement with Aditxt after stockholders did not approve the transaction.
Nov 13, 2025, 9:19 PM
Evofem Biosciences Reports Q3 2025 Financial Results and Business Updates
EVFM
Earnings
Revenue Acceleration/Inflection
M&A
- Evofem Biosciences reported net sales of $5.0 million in the third quarter of 2025, marking a 10% increase compared to $4.5 million in the prior year quarter.
- The company achieved operating income of $1.0 million in Q3 2025, a significant improvement from an operating loss of $2.4 million in Q3 2024, primarily driven by a 42% reduction in total operating expenses to $4.0 million.
- Net loss attributable to common stockholders improved to $1.7 million (or $0.01 per basic and diluted share) in Q3 2025, compared to a net loss of $2.4 million (or $0.02 per basic and diluted share) in Q3 2024.
- Evofem is advancing strategies to reduce manufacturing costs by approximately 50% for both PHEXX® and SOLOSEC®, and SOLOSEC® was submitted for marketing approval in the United Arab Emirates in Q3 2025.
- The merger agreement with Aditxt was terminated in October 2025 after Evofem's stockholders did not approve the transaction.
Nov 13, 2025, 9:05 PM
Evofem Stockholders Reject Aditxt Merger, Company Terminates Agreement
EVFM
M&A
Proxy Vote Outcomes
Delisting/Listing Issues
- Evofem Biosciences, Inc. stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement with Aditxt, Inc. at a Special Meeting of Stockholders held on October 20, 2025.
- As a result, Evofem exercised its rights to terminate the Merger Agreement effective October 20, 2025.
- The company will now pivot to focus on regaining a national listing for its stock and securing capital to catalyze growth, with a goal of achieving sustainable positive EBITDA in 2027.
- For the merger proposal, there were 93,239,872 votes For and 7,208,466 votes Against.
Oct 20, 2025, 9:22 PM
Evofem Stockholders Reject Aditxt Merger, Company Pivots to National Listing and Growth Capital
EVFM
M&A
Proxy Vote Outcomes
Delisting/Listing Issues
- Evofem Biosciences' stockholders did not approve the merger with Aditxt, leading to the termination of the Merger Agreement.
- The company is now pivoting to focus on regaining a national listing for its stock and securing growth capital, with a goal to achieve sustainable positive EBITDA in 2027.
- Evofem will continue its collaboration with Aditxt to commercialize Mitomic™ diagnostic tests for women's health.
- Evofem commercializes two FDA-approved sexual health products, PHEXXI® and SOLOSEC®, and reported its fourth consecutive year of net sales growth in 2024.
Oct 20, 2025, 8:19 PM
Evofem Biosciences Reports "Say Vagina" Campaign Impact and Merger Details
EVFM
M&A
New Projects/Investments
Proxy Vote Outcomes
- Evofem Biosciences announced the conclusion and impact of its August 2025 "Say Vagina" campaign, which generated over 2.5 million views across social media platforms and led to a 130% increase in traffic to PHEXXI.com.
- The campaign also resulted in PHEXXI® becoming the #1 most followed contraceptive brand on social media by healthcare providers.
- Evofem plans to launch SayVaginaStore.com in September, with 100% of proceeds from Say Vagina Month items donated to charity.
- The company filed a Definitive Proxy on September 8, 2025, for a Special Meeting on September 26, 2025, where stockholders will vote on a proposal to approve a merger agreement with Adifem, Inc., a wholly owned subsidiary of Aditxt, Inc..
Sep 11, 2025, 1:18 PM
Evofem Biosciences Amends Merger Agreement and Converts Debt to Preferred Stock
EVFM
M&A
Convertible Preferred Issuance
- Evofem Biosciences, Inc. entered into a Sixth Amendment to its Amended and Restated Agreement and Plan of Merger with Aditxt, Inc. and Adifem, Inc. on August 26, 2025.
- This amendment updated the definition of "Unconverted Company Preferred Stock" to include Series G-1 Convertible Preferred Stock, clarified that the Company will assist in obtaining agreements to exchange Company convertible notes and purchase rights for an aggregate of not more than 89,021 shares of Parent Preferred Stock, and set limits for dissenting shares at 5,932,818 common shares and 202 preferred shares.
- Additionally, on August 22, 2025, Evofem Biosciences, Inc. converted $1,573,000 in senior secured convertible notes into 1,573 shares of Series G-1 Convertible Preferred Stock.
Aug 26, 2025, 12:00 AM
Quarterly earnings call transcripts for Evofem Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more